Danziten Tablet
Product Images NDC 24338-155

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Danziten (NDC 24338-155). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Azurity Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Danziten Inner Carton 71mg (Danziten 71mg Inner Carton Label)

Danziten Inner Carton 71mg (Danziten 71mg Inner Carton Label)
Carton packaging label for DANZITEN (nilotinib) tablets, 71 mg strength, oral tablets. The label states a quantity of 28 tablets per carton, supplied as 2 blister packs of 14 tablets each. It includes storage instructions and dispensing information. Labeler is Azurity Pharmaceuticals, Inc., with manufacturing by Catalent Pharma Solutions, Inc.*
FDA Label Image

Danziten Outer Carton 71mg (Danziten 71mg Outer Carton Label)

Danziten Outer Carton 71mg (Danziten 71mg Outer Carton Label)
Packaging label for Danziten (nilotinib) tablets, 71 mg strength, oral dosage form. Label shows the product name prominently with strength, directions for pharmacists to dispense with medication guide, and warnings to keep out of reach of children. The label states the package contains 112 tablets in four inner carton packs (4x28). Manufactured by Azurity Pharmaceuticals, Inc., with storage instructions and bar code also visible.*
FDA Label Image

Danziten Inner Carton 95mg (Danziten 95mg Inner Carton Label)

Danziten Inner Carton 95mg (Danziten 95mg Inner Carton Label)
Danziten (nilotinib) 95 mg tablets packaging label for human prescription use. The label indicates the dosage form as oral tablets, with 28 tablets per carton containing 2 blister packs of 14 tablets each. It includes pharmacist instructions, storage conditions, and manufacturer information. The labeler is Azurity Pharmaceuticals, Inc.*
FDA Label Image

Danziten Outer Carton 95mg (Danziten 95mg Outer Carton Label)

Danziten Outer Carton 95mg (Danziten 95mg Outer Carton Label)
The image shows the unfolded carton packaging for Danziten (nilotinib) tablets, 95 mg strength. The label indicates the product is oral tablets supplied by Azurity Pharmaceuticals, Inc. The carton contains four inner cartons with 28 tablets each, totaling 112 tablets. The label includes dosing instructions to see prescribing information, warnings to keep out of reach of children, and directions to swallow tablets whole. Manufacturer and distributor addresses are noted, along with a barcode and medication guide instructions.*
FDA Label Image

Danziten Structure (Danziten Structure)

Danziten Structure (Danziten Structure)
Chemical structure of nilotinib, the active ingredient in DANZITEN tablets by Azurity Pharmaceuticals, Inc. The diagram shows the detailed molecular arrangement of nilotinib, including fluorine and nitrogen atoms, alongside an adjacent molecular structure.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A Kaplan-Meier survival curve showing treatment-free survival percentage over time in weeks since treatment-free remission (TFR). The chart includes confidence intervals and displays numbers of patients at risk, events, and censored observations at various time points, with an indication of when therapy was discontinued.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A Kaplan-Meier survival curve graph showing treatment-free survival (%) over time in weeks since treatment-free remission (TFR). The graph includes a solid line representing survival probability, dashed confidence interval lines, and censored observations marked along the curve. Patient counts, event counts, and censored counts are tabulated for various time points, illustrating the number of patients at risk and events over the study period up to approximately 144 weeks.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.